Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Second-generation H1 antihistamine use with survival and immune-related outcomes in lung cancer and melanoma patients receiving immune checkpoint inhibitors.

Leen Alkuttob, Layan Aldib, Mohammmad Amer Al Tamimi et al. Jun 01, 2026 pp. 11153-11153 10.1200/jco.2026.44.16_suppl.11153

11153 Background: Immune checkpoint inhibitors (ICIs) are standard of care for melanoma and lung cancer but are associated...

TP53 loss in relation to mTORC1 activation and autophagy suppression shaping an immune-cold phenotype in microsatellite-stable colorectal cancer.

Eunseuk Lee, Dana Al-Assi, Randy Rueda-Rivera et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15521

e15521 Background: Loss of TP53 is one of the most common alterations in microsatellite-stable colorectal cancer (MSS CRC)...

SARS-CoV-2 infection, vaccination, and MGUS progression with COVID-19 outcomes in multiple myeloma: A systematic review.

Rithika Manjunatha Reddy Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19550

e19550 Background: SARS-CoV-2 infection and vaccination have been associated with immune perturbations that may affect pla...

Profiling <i> <i>NRG1</i> </i> fusions in NSCLC: A comparative analysis of DNA+RNA-NGS and DNA-NGS assays.

Chunxia Su, Wenyan Yu Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20742

e20742 Background: The neuroregulin 1 ( NRG1...

The corticosteroid timing paradox in immune checkpoint inhibitor–treated solid tumors and its association with overall survival: A TriNetX retrospective cohort study.

Nikhil Kumar Kotla, Soumya Kondaveety, Bhavya Vemuri et al. Jun 01, 2026 pp. 11140-11140 10.1200/jco.2026.44.16_suppl.11140

11140 Background: Systemic corticosteroids are frequently used in patients receiving immune checkpoint inhibitors (ICIs) f...

Comparative effectiveness and safety of axicabtagene ciloleucel versus lisocabtagene maraleucel in large B-cell lymphoma: A real-world target trial emulation.

Mohammed Zuber, Chia Jie Tan, Joshua Caballero et al. Jun 01, 2026 pp. 11021-11021 10.1200/jco.2026.44.16_suppl.11021

11021 Background: Axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are approved CD19-directed CAR...

An AI-powered, human-in-the-loop, real-time registry platform to enable clinical trials, pragmatic studies, and prospective external control arms (ProECA) at scale in US community practices.

Luis T. Campos, Laura Guerra, Annette Fontaine et al. Jun 01, 2026 pp. 11058-11058 10.1200/jco.2026.44.16_suppl.11058

11058 Background: Drug development is requiring novel approaches such as prospective external controls to reduce developme...

Beyond uveal melanoma: Genomic landscape and immunogenic profiles of <i>GNAQ</i> and <i>GNA11</i> mutations in metastatic solid tumors.

Minsuk Kwon, Ji Eun Shin, Sunghee Lim et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15115

e15115 Background: Activating mutations in GNAQ and GNA11...

Harnessing OMOP-CDM for multisite collaborations to measure cardiovascular risk factors and cardiovascular disease in the early survivorship period for children, adolescents, and young adults.

David H. Noyd, Erin Sullivan, Danielle Blackburn et al. Jun 01, 2026 pp. 10009-10009 10.1200/jco.2026.44.16_suppl.10009

10009 Background: The Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) is an international effort t...

Definitive bladder/pelvic radiation after enfortumab vedotin–pembrolizumab for advanced urothelial carcinoma.

Andrew Bacotti, Michal Sternschuss, Alyssa Arbuiso et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16589

e16589 Background: Treatment with enfortumab vedotin and pembrolizumab (EV-P) is highly effective in patients (pts) with a...

Neoadjuvant cadonilimab plus chemotherapy for locally advanced gastric/gastroesophageal junction cancer: A single-arm, phase II trial.

Pengfei Zhang, Kun Yang, Chaoxin Xiao et al. Jun 01, 2026 pp. 4100-4100 10.1200/jco.2026.44.16_suppl.4100

4100 Background: Cadonilimab plus chemotherapy is a promising treatment option in the first-line setting of gastric cancer...

Early chemo-induced TME alterations as a predictor of response to PD-1 blockade in AVPC: Single-cell data from C3NIRA.

Anthos Christofides, Sreyashi Basu, Zhong He et al. Jun 01, 2026 pp. 5065-5065 10.1200/jco.2026.44.16_suppl.5065

5065 Background: Aggressive variant prostate cancer (AVPC) criteria enrich for androgen-indifferent disease that is highly...

Real-world incidence, prevalence, and short-term outcomes in young-onset breast cancer.

Safa Saadat Afridi, Susu Zhou, Sumbal Aziz et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13092

e13092 Background: Young-onset breast cancer(diagnosed at age &lt; 40 years) is increasing in incidence,yet contemporary r...

Breast cancer screening uptake and barriers among women in Hue, Vietnam: A cross-sectional survey.

Anh-Khue Nguyen, Qui Tran, Hieu Phan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13530

e13530 Background: Breast cancer is the leading cancer in women in Vietnam, with almost 25,000 cases per year. However, th...

Evaluation framework for monoclonal B-cell lymphocytosis.

Andrienne Mckenzie, Cheryl Mensah Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22571

e22571 Background: Monoclonal B cell lymphocytosis (MBL) is recognized as a precursor to chronic lymphocytic leukemia (CLL...

Discovery from single-cell RNA sequencing profiles of 18 CPTAC glioblastoma patients and validation in bulk profiles of 138 TCGA patients and two human-derived cell lines of a whole-transcriptome predictor of overall survival and drug targets by using quantum mechanics–based AI/ML.

Orly Alter, David B. Oberman, Daniel Shabtai et al. Jun 01, 2026 pp. 3019-3019 10.1200/jco.2026.44.16_suppl.3019

3019 Background: Single-cell, more than bulk, multi-omic data, are small-cohort, noisy, and high-dimensional, and extremel...

Clinical characteristics and neighborhood factors associated with patient survival among adolescents and young adults with bone sarcoma.

Shahrzad A. Zamani, Chloe Chose, Sofia Restrepo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23500

e23500 Background: Compared to pediatric patients, adolescents and young adults (AYA) with bone sarcomas experienc...

Beyond imatinib: Real-world mortality patterns across modern second-line TKIs in CML.

Sonia Babu, Drew Clippert, Darsh Patel et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18594

e18594 Background: Tyrosine kinase inhibitors (TKIs) have altered management and outcomes of chronic myeloid leukemia (CML...

The AI paradox in precision oncology: Prospective blinded validation of large language models against molecular tumor board.

Arun Seshachalam, K Niraimathi Anandan, Tamilarasi Dharaniraj et al. Jun 01, 2026 pp. 11047-11047 10.1200/jco.2026.44.16_suppl.11047

11047 Background: Molecular tumor boards (MTBs) are central to precision oncology but remain limited in accessibility. Lar...

Effect of GLP-1 receptor agonism on anthracycline- and HER2-targeted therapy–induced cardiac dysfunction and systemic inflammation in non-diabetic preclinical models.

Vincenzo Quagliariello, Annabella Di Mauro, Gerardo Ferrara et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12524

e12524 Background: Sequential administration of anthracyclines and HER2-targeted agents represents a highly effective ther...

First-line NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma and pre-existing diabetes: NAPOLI 3 post hoc analysis.

Sreenivasa R. Chandana, Armin Lahiji, Whitney Rhodes et al. Jun 01, 2026 pp. 4195-4195 10.1200/jco.2026.44.16_suppl.4195

4195 Background: Approximately 29% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) present with pre-e...

Metabolic comorbidity burden and oncologic features of early-onset colorectal cancer stratified by hepatic steatosis.

Wesley Dean Boland, Mark Larry Solter, Claire Yin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15696

e15696 Background: Early-onset colorectal cancer (EO-CRC) incidence is rising, and emerging evidence links EO-CRC with met...

Comparative outcomes of [^177Lu]Lu-PSMA-617 versus radium-223 in bone-metastatic castration-resistant prostate cancer: A real-world propensity-matched analysis.

Fathima Shehnaz Ayoobkhan, Fayaz Aijaz Ahmed Khan, Madhu Bhargavi Chandra et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17070

e17070 Background: Two guideline-recognized radiopharmaceuticals differ in mechanism and indication. Radium-223 (Ra-223),...

Pancreatectomy with and without preoperative biliary drainage: A systematic review and meta analysis.

Khaled Saed, Anoosh Farooqui, Arham Khalid Farooq et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16426

e16426 Background: Preoperative biliary drainage (PBD) is commonly performed in patients with obstructive jaundice due to...

Where do adults with pancreatic cancer die in the United States: A retrospective analysis of 25 years.

Syeda Malika Naqvi, Sarim Hassan Shahab, Irza Shaikh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24042

e24042 Background: Pancreatic cancer remains a leading cause of cancer-related morbidity and mortality. With limited survi...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page